Viral microRNA
AssigneesPresident and Fellows of Harvard College, Duke University
InventorsBryan R. Cullen, Jennifer Lin Umbach, Donald M. Coen, Martha F. Kramer, Igor Jurak, David Knipe
Life of this patent
Estimating the term…
Abstract
The present invention relates, in general, to micro RN As and, in particular, to viral microRNAs expressed by Herpes Simplex Vims 1 (HSV-1) or Herpes Simplex Virus 2 (HSV-2), to agents that inhibit such microRNAs and to methods of treatment based on the use of such agents.
Claims20
An isolated nucleic acid sequence consisting of a sequence complementary to the full length of a sequence selected from the group consisting of SEQ ID NOs:
- 26, 27, 29-79 and 113-256.
A DNA-based expression vector comprising a heterologous sequence and a nucleic acid sequence consisting of a sequence selected from the group consisting of SEQ ID NOs:
- 26-79 and 113-256.
An isolated nucleic acid sequence consisting of a sequence of 12-30 nucleotides, said nucleic acid sequence including a sequence of at least 12 contiguous nucleotides complementary to a sequence selected from the group consisting SEQ ID NOs:
- 26-79 and 113-256, said nucleic acid sequence not consisting of a sequence complementary to the full length of SEQ ID NO:28.
An isolated nucleic acid sequence selected from the group consisting of SEQ ID NOs:
- 32, 33, 34, 35, 36, 45, 51, 52, 53, 54, 55, 56, 58, 60, 61, 62, 63, 67, 71, 76 and 79, or a nucleic acid sequence encoded by a sequence selected from the group consisting of SEQ ID NOs:
- 32, 33, 34, 35, 36, 45, 51, 52, 53, 54, 55, 56, 58, 60, 61, 62, 63, 67, 71, 76 and 79, or a nucleic acid sequence consisting of 12-30 nucleotides wherein said nucleic acid sequence includes a sequence of at least 12 contiguous nucleotides complementary to a sequence selected from the group consisting of SEQ ID NOs:
- 32, 33, 34, 35, 36, 45, 51, 52, 53, 54, 55, 56, 58, 60, 61, 62, 63, 67, 71, 76 and 79.
An isolated nucleic acid sequence
- consisting of a sequence of 12-30 nucleotides, said nucleic acid sequence including a sequence of at least 12 contiguous nucleotides complementary to a sequence selected from the group consisting SEQ ID NOs:
- 28-38, 57-71, 117-135 and 203-207, said nucleic acid sequence not consisting of a sequence complementary to the full length of SEQ ID NO:28, or
- consisting of a sequence of 12-30 nucleotides, said nucleic acid sequence including a sequence of at least 12 contiguous nucleotides complementary to a sequence selected from the group consisting SEQ ID NOs:
- 28-38, 57-71, 117-135 and 203-207, wherein said sequence contains at least one chemically modified nucleotide.
Dependencies are inferred from the claim text.